Clinical Trial Update: Dose Escalation and Efficacy Study of mRNA-2416 for Intratumoral Injection Alone and in Combination With Durvalumab for Participants With Advanced Malignancies [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update reports dose-escalation and preliminary efficacy findings for intratumoral mRNA-2416 as a standalone therapy and in combination with …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma
• Ovarian Cancer
• Solid Tumors

Drugs mentioned

• Durvalumab (durvalumab)
• mRNA-2416

Snippet

Sponsor: ModernaTX, Inc. | Conditions: Relapsed/Refractory Solid Tumor Malignancies or Lymphoma, Ovarian Cancer | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2024-07-31